The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro
Contributors
Cagno, Valeria; Magliocco, GaëllePublished in
Basic & Clinical Pharmacology & Toxicology, vol. 128, no. 4, p. 621-624Publication date
2021Abstract
Keywords
- COVID-19
- SARS-CoV-2
- Nilotinib
- Tyrosine kinases inhibitors
UNIGE affiliation entities
Citation (ISO format)
CAGNO, Valeria et al. The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro. In: Basic & Clinical Pharmacology & Toxicology, 2021, vol. 128, n° 4, p. 621–624. doi: 10.1111/bcpt.13537
Main files (1)
Article (Published version)
Identifiers
- PID : unige:154381
- DOI : 10.1111/bcpt.13537
- PMID : 33232578
